ArticleCureus2025
Evaluating the Therapeutic Effect of Dehydroepiandrosterone on Stromal Fibrosis and Endocrine Function in Patients With Resistant Ovary Syndrome: A Case-Control Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundResistant ovary syndrome (ROS) is a rare form of ovarian dysfunction defined by the presence of normal ovarian follicles that fail to respond to gonadotropin stimulation. The adrenal androgen, dehydroepiandrosterone (DHEA), has been studied for its potential in improving ovarian response and reserve. This study investigated the therapeutic effects of DHEA on ovarian stromal fibrosis and hormonal parameters in ROS patients.
methodsA case-control study was conducted on 60 women diagnosed with ROS. Participants were designated as cases treated with DHEA (75 mg/day, 12 weeks) or controls (no supplementation), with 30 participants in each group. Transvaginal ultrasound (TVUS) assessments of ovarian volume, stromal fibrosis grade, and echotexture were performed before and after the treatment. Serum levels of anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), and estradiol (E2) were also analyzed. Statistical analysis was performed using IBM SPSS Statistics for Windows, version 26 (Released 2018; IBM Corp., Armonk, New York, United States). p < 0.05 was considered significant.
resultsNo significant differences were found between the two groups at baseline. By the end of 12th week, the DHEA group showed a significant improvement: 18 (60%) participants experienced a reduction in stromal fibrosis grade most commonly from Grade 2 to Grade 1, 21 (70%) showed an increase in their ovarian volume, and 14 (47%) had normalized stromal echo-texture. Changes in hormone levels were also observed, including a rise in AMH in 13 individuals (45%), a decrease in FSH in eight (28%), and an increase in estradiol in 10 (34%), which were greater than in the control group (p < 0.05).
conclusionSupplementation with DHEA greatly improved the ovarian stromal structure and hormonal function in ROS patients. Due to its anti-fibrotic and functional benefits, DHEA may prove to be a promising adjunctive therapy in the management of the challenging ROS condition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.